Status:
COMPLETED
Randomised Study to Compare the Efficacy of AZD6244 vs TMZ
Lead Sponsor:
AstraZeneca
Conditions:
Melanoma
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
The primary purpose of this study is to compare the efficacy of AZD6244 (ARRY-142886) with temozolomide in patients with advanced melanoma
Eligibility Criteria
Inclusion
- Diagnosed with late stage malignant melanoma
- Aged 18 or over
- Female patients must be post-menopausal or with negative urine pregnancy test if pre-menopausal
Exclusion
- Any previous radiotherapy or chemotherapy (palliative radiotherapy is acceptable)
- Participation in any other trial with an investigational product within the previous 30 days
Key Trial Info
Start Date :
July 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 1 2013
Estimated Enrollment :
239 Patients enrolled
Trial Details
Trial ID
NCT00338130
Start Date
July 1 2006
End Date
July 1 2013
Last Update
August 13 2014
Active Locations (33)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Santa Monica, California, United States
2
Research Site
Aurora, Colorado, United States
3
Research Site
Miami Beach, Florida, United States
4
Research Site
Niles, Illinois, United States